Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Single User License: $2750 Member Price: FREE Buy Now

• Membership Options

Report Highlights

The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets.  BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares.  Technological issues include the latest trends and developments.  The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry has carried out this study.  Its project manager is Shalini S. Dewan, who holds a Master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience.  She has covered such research topics as compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid.  Shalini was awarded a Gold Medal by the Prime Minister of India for her work, and she has collaborated with top companies in India and in the U.S. Her other reports with BCC are Reagents for Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs:  Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.